Drug Use Surveillance of Takecab for "Supplement to Helicobacter Pylori Eradication"

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

560 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-09-01

Study Completion Date

2017-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the safety and efficacy on participants receiving first-line eradication and second-line eradication including vonoprazan (Takecab) tablets (triple therapy) in the routine clinical setting.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Nexium Capsules Helicobacter Pylori Specific Clinical Experience Investigation

NCT01435525

Gastric Ulcer Duodenal Ulcer Gastric Mucosa-associated Lymphoid Tissue (MALT) +2 more

COMPLETED

Efficacy of TAK-438, Amoxicillin and Clarithromycin in the First Line Eradication of H. Pylori

NCT01505127

H. Pylori Infection

COMPLETED PHASE3

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of TNP-2198 Capsules in Asymptomatic Participants With Helicobacter Pylori Infection

NCT06081712

Helicobacter Pylori Infection

COMPLETED PHASE1

14-day PCAB-based High-dose Dual Therapy and14-day PCAB-based Triple Therapy vs 14-day PPI-based Reverse Hybrid Therapy

NCT05191888

Helicobacter Pylori Eradication

UNKNOWN PHASE4

Efficacy and Safety of Dual Therapy for Helicobacter Pylori Eradication

NCT05469685

Helicobacter Pylori Infection

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The drug being tested in this study is called Vonoprazan (Takecab). Vonoprazan is being tested to treat people who have gastric ulcer, duodenal ulcer, gastric mucosa-associated lymphoid tissue (MALT) lymphoma, idiopathic thrombocytopenic purpura, stomach following endoscopic treatment of early gastric cancer, or H. pylori gastritis. This study will look at the presence or absence of new concerns regarding the safety of triple therapy with Vonoprazan tablets, amoxicillin, and clarithromycin (first-line eradication) and triple therapy with Vonoprazan tablets, amoxicillin, and metronidazole (second-line eradication) for supplemental Helicobacter pylori (H. pylori) eradication in the routine clinical setting. The study will enroll approximately 500 patients.

First-line eradication

* Vonoprazan 20 mg / Proton pump inhibitor
* Amoxicillin hydrate 750 mg
* Clarithromycin 200 mg

If H. pylori eradication with a three-drug regimen comprising vonoprazan or proton pump inhibitor + amoxicillin hydrate + clarithromycin has been unsuccessful.

Second-line eradication

* Vonoprazan 20 mg
* Amoxicillin hydrate 750 mg
* metronidazole 250 mg

This multi-center trial will be conducted in Japan.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastric/Duodenal Ulcer, Gastric MALT Lymphoma, Idiopathic Thrombocytopenic Purpura, or H. Pylori Gastritis, and Other

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vonoprazan 20 mg

For adults, the following three-drug regimen will be administered orally at the same time twice daily for 7 days: 20 mg dose of vonoprazan, 750 mg (potency) dose of amoxicillin hydrate, and 200 mg (potency) dose of clarithromycin. The dose of clarithromycin may be increased as clinically warranted. However, dosage should not exceed 400 mg (potency)/dose twice daily. If H. pylori eradication with a three-drug regimen comprising vonoprazan or proton pump inhibitor + amoxicillin hydrate + clarithromycin has been unsuccessful, as an alternative treatment, the following three drugs will be administered orally twice daily for 7 days to adults: 20 mg dose of vonoprazan, 750 mg (potency) dose of amoxicillin hydrate, and 250 mg dose of metronidazole. Participants will receive interventions as part of routine medical care.

Vonoprazan

Intervention Type DRUG

Vonoprazan tablets

Amoxicillin hydrate

Intervention Type DRUG

Amoxicillin hydrate (potency)

Clarithromycin

Intervention Type DRUG

Clarithromycin (potency)

Metronidazole

Intervention Type DRUG

Metronidazole

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vonoprazan

Vonoprazan tablets

Intervention Type DRUG

Amoxicillin hydrate

Amoxicillin hydrate (potency)

Intervention Type DRUG

Clarithromycin

Clarithromycin (potency)

Intervention Type DRUG

Metronidazole

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Takecab tablets TAK-438

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants receiving H. pylori eradication treatment for the first time
* Participants for whom H. pylori eradication with Takecab tablets or proton pump inhibitor + amoxicillin + clarithromycin was found unsuccessful and who will receive eradication treatment with amoxicillin and metronidazole

Exclusion Criteria

* Participants with previous history of hypersensitivity to ingredients in Takecab tablets
* Participants taking atazanavir sulfate or rilpivirine hydrochloride

Eligible Sex

ALL

Accepts Healthy Volunteers

No